TREMEAU PHARMACEUTICALS
Tremeau Pharmaceuticals is a Massachusetts based privately funded clinical stage company focused on commercializing non-opioid pain therapies targeting serious rare diseases impacted by the cyclooxygenase (COX) or prostanoid pathways. They focus exclusively on orphan or unique disease states with high unmet medical need.
TREMEAU PHARMACEUTICALS
Industry:
Clinical Trials Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tremeaurx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
115.2 M USD
Technology used in webpage:
SPF Amazon Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Amazon Route 53 Amazon CloudFront Slack
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Current Employees Featured
Founder
Investors List
Gurnet Point Capital
Gurnet Point Capital investment in Private Equity Round - Tremeau Pharmaceuticals
Official Site Inspections
http://www.tremeaurx.com Semrush global rank: 10.56 M Semrush visits lastest month: 221
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Tremeau Pharmaceuticals"
Tremeau Pharmaceuticals
Committed to the communities we serve. Our goal is to deliver non-opioid pain therapies for people living with pain. See our approachSee details»
Tremeau Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Tremeau Pharmaceuticals is a Massachusetts based privately funded clinical stage company focused on commercializing non-opioid pain therapies …See details»
Tremeau Pharmaceuticals Company Profile | Management and
Www.tremeaurx.com Tremeau Pharmaceuticals Profile and History Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well …See details»
Overview, News & Similar companies - ZoomInfo.com
Oct 20, 2022 Who is Tremeau Pharmaceuticals. Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined …See details»
Approach - Tremeau
Approach. Tremeau was founded with the goal of developing and delivering non-opioid pain therapies for well-defined patient populations.See details»
Tremeau Pharmaceuticals, Inc. | LinkedIn
Tremeau Pharmaceuticals, Inc. | 904 followers on LinkedIn. Leading the way for those left behind in pain | Tremeau is a Massachusetts-based pharmaceutical company focused on providing …See details»
Tremeau Pharmaceuticals - Craft
Tremeau Pharmaceuticals has 5 employees at their 1 location and $5.2 m in total funding,. See insights on Tremeau Pharmaceuticals including office locations, competitors, revenue, …See details»
Tremeau Pharmaceuticals, Inc. - Company Profile - Corporation Wiki
Tremeau Pharmaceuticals, Inc. Overview. Tremeau Pharmaceuticals, Inc. filed as a Foreign For-Profit Corporation in the State of Texas on Wednesday, May 12, 2021 and is approximately …See details»
Tremeau Pharmaceuticals, Inc.'s financial review - Apollo.io
Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.Tremeau's …See details»
Tremeau Pharmaceuticals - Company Info, Employees
View Tremeau pharmaceuticals tremeaurx.com location in 53 main st, concord, massachusetts, 01742, united states, revenue, industry and description. Find related and similar companies as …See details»
Tremeau Pharmaceuticals - Golden
Golden has been acquired by ComplyAdvantage. Read about it here . Tremeau Pharmaceuticals. Tremeau Pharmaceuticals is a non-opioid pain therapies.See details»
Tremeau pharmaceuticals, inc. information - Employees, Contact info
View information on-Tremeau pharmaceuticals, inc. (tremeaurx.com),Located in . Find over 9 employees information, adress, official website, private emails, phone numbers, revenue, …See details»
Tremeau - VentureRadar
Website: https://tremeau.com/ Develops treatments for acute and chronic pain in specific patient populations using COX-2 selective NSAIDs, aiming to reduce reliance ...See details»
Pipeline - tremeau.com
Assets. At Tremeau, we focus on patient populations whose pain management needs are not well-satisfied by the current standard of care. Our unique approach to acute and chronic pain …See details»
Articles about Tremeau Pharmaceuticals - BioSpace
About Tremeau Pharmaceuticals. Tremeau is a new pharmaceutical company focused on providing non-opioid treatment options for rare diseases and other unique patient conditions …See details»
Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program …
Apr 1, 2021 Investment will enable Tremeau to advance the clinical development of TRM-201 (rofecoxib)Tremeau has gained agreement with FDA to initiate a pivotal Phase III trial for TRM …See details»
Tremeau Completes $5.2M Equity Raise to Fund Non-Opioid Pain …
CAMBRIDGE, Mass., Feb. 15, 2018 /PRNewswire/ -- Tremeau Pharmaceuticals, a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases, …See details»
Strategy - Tremeau
Our Strategy. Many people in pain have been left behind by the current standard of care. Treatment options are limited, which forces many to resort to opioid therapy, use drugs with …See details»
Tremeau Receives May Proceed Notification From FDA For Phase …
Source link. This is the second IND opened for a clinical program developing Tremeau’s lead asset, TRM-201 (rofecoxib) Previously marketed as VIOXX, rofecoxib has a well-established …See details»
Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program …
Dec 9, 2020 Corey MacGregor [email protected] For media inquiries: Ellen Murphy 917-628-8097 [email protected]. Release Summary.See details»